Gritstone Oncology logo
Gritstone Oncology GRTS

Quarterly report 2024-Q2
added 08-13-2024

report update icon

Gritstone Oncology Balance Sheet 2011-2026 | GRTS

Annual Balance Sheet Gritstone Oncology

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-15.9 M -30.9 M -84.2 M - -33.9 M -41.7 M -28.5 M -12.4 M - - - - -

Long Term Debt

40.1 M 19.3 M 18.9 M - - - - - - - - - -

Long Term Debt Current

6.9 M 5.29 M 7.48 M 5.87 M 2.5 M - - - - - - - -

Total Non Current Liabilities

- - - - 30.5 M 25.3 M 12.4 M 2.24 M - - - - -

Total Current Liabilities

27.3 M 34.8 M 40 M 27 M 19.5 M 15.1 M - - - - - - -

Total Liabilities

126 M 70 M 62 M 54.8 M 50 M 40.4 M 20 M 4.73 M - - - - -

Deferred Revenue

2.35 M 5.13 M 17.2 M 3.48 M 4.96 M 5.34 M - - - - - - -

Retained Earnings

-660 M -521 M -401 M -326 M -221 M -126 M -61.6 M -20.2 M - - - - -

Total Assets

178 M 241 M 278 M 222 M 184 M 190 M 117 M 46.4 M - - - - -

Cash and Cash Equivalents

63 M 55.5 M 111 M 171 M 57.4 M 52.2 M 40 M 12.4 M - - - - -

Book Value

51.8 M 171 M 216 M 167 M 134 M 149 M 97.3 M 41.7 M - - - - -

Total Shareholders Equity

51.8 M 171 M 216 M 167 M 134 M 149 M 97.3 M 41.7 M - - - - -

All numbers in USD currency

Quarterly Balance Sheet Gritstone Oncology

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

40.5 M 40.3 M 40.1 M 29.9 M 29.7 M - 19.3 M 19.3 M - 18.7 M 18.9 M 19.8 M 16.2 M 17.6 M 19.2 M 19.2 M 19.2 M 19.2 M - 21 M 21 M 21 M 10.5 M 10.5 M 10.5 M 10.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

120 M 123 M 126 M 113 M 113 M - 70 M 68.4 M - 54.3 M 62 M 63.3 M 45.4 M 47.6 M 54.8 M 54.8 M 54.8 M 54.8 M 50 M 50 M 50 M 50 M 40.4 M 40.4 M 40.4 M 40.4 M 20 M 20 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

698 K 1.28 M 2.35 M 1.3 M 2.82 M - 5.13 M 8.69 M - 12.3 M 17.2 M 13.8 M 2.94 M 3.39 M 3.48 M 3.48 M 3.48 M 3.48 M 4.96 M 4.96 M 4.96 M 4.96 M 5.34 M 5.21 M 5.34 M 5.34 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-723 M -700 M -660 M -629 M -590 M - -521 M -490 M - -430 M -401 M -372 M -343 M -318 M -326 M -326 M -326 M -326 M -221 M -221 M -221 M -221 M -126 M -126 M -126 M -126 M -61.6 M -61.6 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

143 M 137 M 178 M 187 M 223 M - 241 M 205 M - 243 M 278 M 271 M 224 M 247 M 222 M 222 M 222 M 222 M 184 M 184 M 184 M 184 M 190 M 190 M 190 M 190 M 117 M 117 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

50.9 M 42.4 M 63 M 29.5 M 49.1 M 54.5 M 55.5 M 76.9 M 80.3 M 69.2 M 93.3 M 148 M 64.1 M 109 M 170 M 170 M 170 M 170 M 57.4 M 57.4 M 57.4 M 57.4 M 52.2 M 52.2 M 52.2 M 52.2 M 39 M 39 M - - 12.4 M - - - 23.9 M - - - - - - - - - - - - - - - - - - -

Book Value

22.2 M 14 M 51.8 M 74 M 110 M - 171 M 137 M - 189 M 216 M 208 M 179 M 199 M 167 M 167 M 167 M 167 M 134 M 134 M 134 M 134 M 149 M 149 M 149 M 149 M 97.3 M 97.3 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

22.2 M 14 M 51.8 M 74 M 110 M 141 M 171 M 137 M 163 M 189 M 216 M 208 M 179 M 199 M 167 M 167 M 167 M 167 M 134 M 134 M 134 M 134 M 149 M 149 M 149 M 149 M 97.3 M 97.3 M - - 41.7 M - - - 24 M - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Gritstone Oncology, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Amgen Amgen
AMGN
$ 350.13 2.98 % $ 188 B usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.73 3.33 % $ 3.99 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
argenx SE argenx SE
ARGX
$ 783.17 2.32 % $ 25 B niderlandNiderland
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.48 8.82 % $ 394 M britainBritain
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.57 5.59 % $ 3.13 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.64 2.25 % $ 27.2 B germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.82 1.6 % $ 9.19 B australiaAustralia
Burford Capital Limited Burford Capital Limited
BUR
$ 4.62 1.54 % $ 742 M britainBritain
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.68 4.28 % $ 16.8 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.05 0.66 % $ 6.64 B israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cabaletta Bio Cabaletta Bio
CABA
$ 3.05 -0.5 % $ 306 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.93 4.62 % $ 368 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 2.83 2.91 % $ 7.38 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.73 3.59 % $ 203 M usaUSA